Exercise Training Volume and the Fitness-fatness Index in Adults With Metabolic Syndrome: A Randomised Trial

Joyce S. Ramos (joyce.ramos@flinders.edu.au)  
Flinders University  https://orcid.org/0000-0001-8693-6800

Lance C. Dalleck  
Western Colorado University

Mackenzie Fennell  
Flinders University

Alex D. Martini  
Flinders University

Talita R. Welmans  
Flinders University

Rebecca Stennett  
The University of Queensland

Shelley E. Keating  
The University of Queensland

Robert G. Fassett  
The University of Queensland

Jeff S. Coombes  
The University of Queensland

Original Research Article

Keywords: fitness fatness index, interval training, metabolic syndrome

DOI: https://doi.org/10.21203/rs.3.rs-534159/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background** Cardiorespiratory fitness and fatness (notably central obesity) are mediating factors of the metabolic syndrome (MetS), and consequent cardiovascular disease (CVD)/mortality risk. The fitness-fatness index (FFI) combines these factors and has been reported to be a better indicator of CVD and all-cause mortality risk, beyond the capacity of either fitness or fatness alone.

**Objective** This study sought to investigate the effects of different exercise volumes on FFI in adults with MetS.

**Methods** This was a sub-study of the ‘Exercise in the prevention of Metabolic Syndrome’ (EX-MET) multicenter trial. Ninety-nine adults diagnosed with MetS according to the International Diabetes Federation criteria were randomized to one of the following 16-week exercise interventions: i) moderate-intensity continuous training (MICT) at 60-70% HRpeak for 30 min/session (n=34, 150 min/week); ii) 4 x 4 min bouts of high-intensity interval training at 85-95% HRpeak, interspersed with 3-min active recovery at 50-70% HRpeak (n=34, 38min/session, 114 mins/week); and iii) 1 x 4 min bout of HIIT at 85-95% HRpeak (n=31, 17 min/session, 51 min/week). Cardiorespiratory fitness (peak oxygen uptake, $\dot{V}O_2$peak) was determined via indirect calorimetry during maximal exercise testing and fatness was the ratio of waist circumference-to-height (WHtR). FFI was calculated as $\dot{V}O_2$peak in metabolic equivalents (METs) divided by WHtR. A clinically meaningful response to the exercise intervention was taken as a 1 FFI unit increase.

**Results** Seventy-seven participants completed pre and post testing to determine FFI. There was a greater proportion of participants who had a clinically meaningful change in FFI following high-volume HIIT (60%, 15/25) and low-volume HIIT (65%, 17/26) compared to MICT (38%, 10/26), but with no significant between-group difference (p=0.12). A similar trend was found when a sub-analysis comparing the FFI between those with type 2 diabetes (MICT, 33%, 3/9; high-volume HIIT, 64%, 7/11; and low-volume HIIT, 58%, 7/12) and without type 2 diabetes (MICT, 41%, 7/17; high-volume HIIT, 57%, 8/14; low-volume HIIT, 71%, 10/14).

**Conclusion** This study suggests that the response to changes in FFI in adults with MetS is affected by aerobic exercise intensity.

**Key Points**

- Low- or high-volume high-intensity interval training (HIIT) may induce a higher proportion of likely responders to a clinically significant improvement in fitness-fatness index (FFI) compared to moderate-intensity continuous training (MICT).
- A similar trend was found when a sub-analysis comparing the FFI between those with or without type 2 diabetes.
- The main finding of this study was that exercise intensity affects the responsiveness of individuals with MetS to improvements in FFI.

Introduction

Metabolic syndrome (MetS) is the clustering of cardiovascular disease risk factors (1), increasing an individual's susceptibility to type 2 diabetes (T2D) and subsequent cardiovascular disease (CVD) (2) and mortality (3). Cardiorespiratory fitness (4) and fatness (5) are mediating factors of MetS and thus have been considered viable targets in the prevention of T2D and CVD-related mortality in those diagnosed with the syndrome. Recently, Sloan et al. (6) developed an index that combines the interaction between fitness and fatness; the Fitness Fatness Index (FFI), calculated as cardiorespiratory fitness divided by waist circumference-to-height ratio (WHtR). This index has been reported to be a better indicator of incident T2D (6, 7), and all-cause and CVD-specific mortality risk, beyond the capacity of either fitness or fatness alone (8). Edward and Loprinzi (8) showed that a 1-FFI-unit increase is associated with a 9% and 11% reduction in all-cause and CVD-specific
mortality, respectively. FFI can therefore be considered a widely accessible clinical tool that can help practitioners better monitor the risk of developing T2D and premature mortality in those with MetS.

Interestingly, the association between an FFI increase and reduced risk of all-cause mortality has been reported to be driven more by the favorable effects of fitness (9), suggesting the importance of tailoring exercise programs towards augmenting fitness as a primary objective. The current exercise guideline of 150 mins per week of moderate-intensity continuous training (MICT) has long been established as an effective intervention to improve fitness and cardiovascular risk factors constituting the MetS (10). However, high-volume high-intensity interval training (HIIT) has been demonstrated to increase fitness more than MICT (11), specifically in people with MetS (12). In addition, Tjonna et al. (13) have also shown that low-volume HIIT (1HIIT, 1 x 4 min interval at 90% peak heart rate [HRpeak]) improves fitness to a similar extent as high-volume HIIT (4HIIT, 4 x 4 min intervals at 90% HRpeak, interspersed by 3 min active recovery). This is an exciting finding given that time constraint is often the most cited barrier to long-term exercise adherence (14). The impact of different exercise volumes on FFI however, has yet to be explored. The aim of this study is to therefore investigate the effects of different exercise volumes on FFI in adults with MetS. We hypothesised that low-volume HIIT will be as efficacious as high-volume HIIT and MICT in augmenting FFI in individuals with MetS. Based on our previous findings comparing people with and without T2D (15), we also aimed to determine the effect of the different training interventions on FFI in those with and without this condition.

**Methods**

Participants in this study were part of the ‘Exercise in prevention of Metabolic Syndrome (EX-MET)’ international multicenter project described previously (16). This-sub-study investigated the change in FFI values in participants recruited from the trial site at Brisbane, Australia. Recruitment was conducted through several methods: i) a website was developed to serve as a recruitment link for social platforms and the University’s online magazine; ii) referrals from medical practitioners at the Princess Alexandra Hospital; and iii) advertising through posters, newspapers, television news and flyers disseminated across the university and local health care centers. Prospective participants were excluded if they present with any of the following: recent myocardial infarction (last four weeks), unstable angina, uncompensated heart failure, severe valvular heart disease, uncontrolled hypertension, pulmonary disease, cardiomyopathy, and kidney failure. Written and oral consent were obtained from all participants prior to inclusion. Ninety-nine individuals diagnosed with MetS according to the International Diabetes Federation criteria (17) were included and randomized into the following exercise groups (stratified by age, sex, and center): i) MICT (n = 34); ii) 4HIIT (n = 34); and iii) 1HIIT (n = 31) (Fig. 1). The randomization procedure was performed via a software employing random permuted blocks. De-identified details of participants eligible were entered into an online system to acquire group allocation.

Before and after the 16-week exercise interventions, participants underwent several tests at the university’s laboratory (Human Movement and Nutrition Sciences Building, St Lucia Campus, The University of Queensland, QLD, Australia) to assess the primary (FFI) and secondary outcome measures (MetS risk factors and body composition). Participants were instructed to refrain from strenuous activities for at least 48 hours, and caffeine and alcohol for at least 24 hours before each examination. All assessments were conducted at approximately the same time of the day (morning, ± 2 hours). This study was approved by the Medical Research Ethics Committee, The University of Queensland (Brisbane, Australia).

**Metabolic syndrome**

To determine the participants’ eligibility for the study, the following assessments were conducted after a 12-hour fast: i) brachial systolic and diastolic blood pressure; ii) fasting lipid profile and glucose-level; and iii) anthropometric measures (height, waist circumference, weight, and hip circumference). Details of these assessments have been reported previously (18).

**Fitness Fatness Index**
The FFI was calculated as the ratio between cardiorespiratory fitness, expressed as the metabolic equivalent (MET), and WHtR. Waist circumference and height were measured according to the protocols presented in Coombes and Skinner (19). The WHtR was calculated by dividing the waist circumference in cm by height in cm. Cardiorespiratory fitness depicted as the peak oxygen uptake ($V_{\text{O}_2}\text{peak}$, mL/kg/min) was assessed via indirect calorimetry using the Parvo Medics TrueOne 2400 and Metamax II system (Cortex, Leipzig, Germany) during a graded maximal exercise test. $V_{\text{O}_2}\text{peak}$ was determined as the highest 15-second time averaged $V_{\text{O}_2}$, expressed relative to the participant’s mass in mL/kg/min. $V_{\text{O}_2}\text{peak}$ in mL/kg/min was subsequently converted to METs by dividing it by 3.5 mL/kg/min. A cycle or treadmill ergometer was used during the test according to the participants’ preferred training method during the supervised exercise sessions or orthopedic limitations. In order to standardize nutrition for the test, participants were provided with a liquid nutritional supplement (Sustagen, 250 mL, Dutch Chocolate, Nestle, Gympie QLD, Australia) to consume two hours before the assessment. All tests were preceded with an 8-minute warm-up which included 2 stages (stage 1 warm-up: 4 km/h at 0% incline or 50–60 revolutions per minute [rpm] at 0 W; stage 2 warm-up: 4 km/h at 4% incline or 50–60 rpm at 25 W). The speed (individualized: within 6–9 km/h) and load (2% incline or 50 W) were subsequently increased each minute until exhaustion. Standardized verbal cues were provided throughout the graded exercise test to motivate participants to reach maximal effort.

Body composition

Dual-energy X-ray absorptiometry (DEXA; Hologic QDR 4500 version 12.6) was used to assess pre- and post-intervention measures of body fat indices (total body and regional [android and gynoid] fat distributions [%]) and lean mass. Participants were required to be in a 12-hr overnight fasted state for this assessment.

Training protocol

The MICT group completed five exercise sessions per week, whilst the HIIT group trained three times per week (at least a day between sessions). All participants were required to attend two supervised sessions, out of the prescribed weekly sessions, at The University of Queensland exercise laboratory. Both exercise heart rate and rating of perceived exertion (RPE) were monitored and recorded throughout the exercise sessions using a heart rate monitor (Polar Electro, Kempele, Finland) and 6–20 Borg scale (20). Participants recorded HR and RPE data during the unsupervised sessions in a training log. The MICT group trained continuously for 30 minutes at 60–70% peak heart rate (HRpeak)/RPE of 11–13 on the Borg Scale. Whereas each 4HIIT and 1HIIT session began with a 10-minute warm-up and concluded with a 3-minute cool-down. The 4HIIT intervention included four bouts of 4-minute intervals performed at 85–95% HRpeak/RPE of 15–17 on the Borg scale, interspersed with 3-min of active recovery performed at 50–70% HRpeak, totaling 38 minutes per session. The 1HIIT intervention comprised of one 4-minute bout of exercise performed at 85–95% HRpeak/RPE of 15–17 on the. Borg scale, totaling 17-minutes per session. All participants were required to attend two supervised sessions per week at The University of Queensland, while the remaining session/s were performed unsupervised.

Statistical analysis

Data were analysed using the SPSS version 25 package (IBM, New York, NY, USA). Chi-square tests were used to compare exercise adherence between exercise intervention groups. Analysis of covariance (ANCOVA) was used to determine the between-group difference in the change in continuous variables from pre- to post-intervention, with the change-value assigned as the dependent variables and the baseline value as the covariate. A paired t-test or its non-parametric equivalent was used to determine within-group differences in continuous variables. Continuous variables are presented as mean ± standard deviation or median (range), whilst categorical variables are reported as frequencies.

To determine individual FFI training responsiveness, delta values (post-intervention value minus pre-intervention value) were calculated. A participant was considered a likely responder if the delta FFI value was ≥ 1 unit. Chi square tests were used to analyse the proportion of training response for FFI with subsequent Cramer’s V test to quantify effect size. Significance level was set at p < 0.05.
Results

Seventy-seven out of the 99 participants recruited as part to the EX-MET trial conducted from January 2013 to August 2015 had complete pre- and post-intervention data to determine the primary outcome of the study (Figure 1). Table 1 provides the baseline data of the 77 participants. The MICT, 4HIIT, and 1HIIT groups completed 89 ± 13%, 88 ± 10%, and 89 ± 14% of the prescribed training sessions, respectively (group difference, p=0.54). There were no reported physical injuries that were directly related to the prescribed exercise interventions.

Fitness-Fatness Index

The magnitude of FFI increase from baseline was higher in the HIIT groups (4HIIT, +16%; 1HIIT, +11%) compared to MICT (+7%), but with no significant difference between groups (p=0.30) (Table 2). A similar trend was found when comparing those without T2D (4HIIT, +15%; 1HIIT, +11%; MICT, +7%; between groups, p=0.83; Table 3) or with T2D (4HIIT, +17%; 1HIIT, +10%; MICT, +5%; p=0.21; Table 4).

Figure 2 presents the proportion of likely responders and likely non-responders to a clinically meaningful change in FFI. In all participants, there was a greater proportion of participants who responded to a clinically meaningful change in FFI following high-volume HIIT (60%, 15/25) and low-volume HIIT (65%, 17/26) compared to MICT (38%, 10/26), but with no significant between-group difference (p=0.12). A sub-analysis that compared participants with or without T2D showed that low-volume HIIT (71%, 10/14) induced a greater proportion of likely responders to a clinical change in FFI compared to MICT (41%, 7/17) and high-volume HIIT (57%, 8/14) in those without T2D, but with no significant between-group difference (p=0.24). Whereas in those with T2D, MICT (33%, 3/9) had a lower proportion of likely responders to a clinically significant change in FFI compared to high-volume HIIT (64%, 7/11) and low-volume HIIT (58%, 7/12), with no between-group difference (p=0.36).

Tables 2-4 shows a similar pattern of change in relative VO₂peak within- and between-groups, with small changes in WHtR following the exercise programs.

Body composition

Tables 2-4 present negligible changes in total body fat (MICT, -1%; 4HIIT, -1%; 1HIIT, -1%), trunk fat (MICT, -1%; 4HIIT, -1%; 1HIIT, -1%), android fat (MICT, -1%; 4HIIT, -2%; 1HIIT, -2%), and gynoid fat (MICT, -1%; 4HIIT, -2%; 1HIIT, -2%) following all exercise interventions.

Discussion

This is the first study to investigate changes in FFI following different exercise volumes in adults with MetS. The main finding is that HIIT, regardless of the training volume (high-volume HIIT, 114 min/week; low-volume HIIT, 51 min/week) induced a greater proportion of likely responders to a clinically significant improvement in FFI (high volume HIIT; 60%; low-volume HIIT, 65%) compared to 150 min per week of MICT (38%), albeit no significant difference between groups. This is an important finding as it has been reported that only about 30% of the Australian population participate in regular exercise (Brown et al. 2002), with time deficiency as the most reported culprit (Trost et al. 2002).

Consistent with a previous study (9), the proportion of participants who met the clinical threshold to a meaningful FFI change in the present study appears to be driven by an increase in fitness, rather than a reduction in fatness. Our study also showed a similar pattern in inter-individual VO₂peak changes between exercise groups, whereas WHtR showed negligible change magnitude from pre-to post-intervention. This is further supported by the lack of significant changes in our body fat indices derived via a DEXA scan which is regarded as a robust method of assessing body composition (21). Williams et al. (22) also found a similar trend in inter-individual VO₂peak changes relative to the present study, with high-volume HIIT (31%) and low-volume HIIT (16%) also showing more likely responders to a clinically significant improvement in VO₂peak compared to MICT (21).
In parallel with a clinical FFI change, the present study also found a greater number of participants in the HIIT groups who reversed the MetS (n = 9) compared to the MICT group (n = 1), which was also previously reported by our group (23). Although MetS significantly increases one's risk of CVD-related mortality, it has been reported that fit individuals with MetS are less susceptible to CVD compared to less fit counterparts, despite the existence of central obesity as a component of this syndrome (3). These findings, therefore, collectively underscore the importance of targeting fitness over fatness in improving cardiovascular health. We hypothesise that the importance of targeting fitness improvement over fat-loss in reducing MetS incidence could be attributable to increased protection against a mismatch between oxygen demand and supply that typically occurs in excess adipose tissue, resulting in hypoxia-induced necrosis of this excess adipose tissue (24). This could have in turn led to the prevention of subsequent insulin resistance, inflammation, and oxidative stress, which are all factors known to exacerbate and promote the clustering of CVD risk factors constituting the MetS (25).

Our sub-analysis also showed that in those with T2D, there is a similar pattern in inter-individual response to a clinical meaningful FFI change following the different exercise interventions (n = 32; MICT, 33%; high-volume HIIT, 64%; low-volume HIIT, 58%). However, in those without T2D (n = 45), low-volume HIIT (71%) appeared to induce a greater proportion of likely responders compared to larger exercise volumes (MICT, 41%; 4HIIT, 57%), but with no significant difference between groups. This highlights the potential importance of exercise intensity over exercise duration as a prophylactic against incident T2D and CVD. As little as 4 min of high-intensity exercise performed three times a week should therefore be at least recommended as a preventative strategy to reduce risk of T2D and CVD-related mortality at the population level. Our results are consistent with a previous study (26) which showed that exercise intensity is a more important factor relative to exercise volume in optimising physiological stress to maximise adaptations of factors contributing to a positive fitness response to training. Our results are also supported by Ross et al. (27), who reported that at fixed amount of exercise (energy expenditure, kcal), increasing exercise intensity results in elimination of non-responders to exercise (27).

It should be noted that we also found a wide variability in FFI changes in response to our 16-week training interventions (MICT, 4HIIT, 1HIIT, Fig. 2). This is in agreement with previous findings that not all individuals, irrespective of baseline status (i.e. age, sex, fat mass, fat free mass, weight, and race) (28, 29), respond positively to a specific dose of standardised exercise, with considerable individual variability in training adaptations including so-called 'non-responders' and, in some cases, 'adverse responders'. The absence of a personalised approach to the exercise prescription has been put forth to explain the variability in response to exercise (30). It has been purported that a more individualised approach to exercise prescription may enhance training efficacy and limit training unresponsiveness. This notion is supported by Wolpern et al. (31) which showed that when exercise intensity is adjusted according to a 'personalized prescription' or threshold-based model (i.e. ventilatory threshold), a more favourable change in fitness was evident in 100% of participants compared to only 41.7% when the exercise intensity was 'standardised' or prescribed according to a relative percent method (i.e. % heart rate reserve [HRR]). Indeed, it has been put forth that the response variability following a 'standardized exercise prescription' may be attributable to the inability of this method to account for individual metabolic difference (32). It is plausible that the standardized exercise dose implemented in the present study and others (32) is insufficient to overcome the threshold to promote fitness improvement or exercise responders in all participants. Likewise, a standardised exercise prescription-induced 'adverse response' may also result from an overestimation or underestimation of the required exercise dosage to foster a positive outcome.

**Limitations**

The main limitation of this study is the standardised protocol (% heart rate peak and RPE) used to prescribe the intensity of the exercise interventions, possibly influencing the variability noted in the exercise response. As previously mentioned, it would have been more informative to personalise the intensity prescription using a threshold-based model, for example. Future studies are encouraged to utilise this prescription method to determine its impact on the exercise response.

**Conclusion**
The main finding was that exercise intensity affects the responsiveness of individuals to improvements in FFI. Specifically, our study shows that HIIT, regardless of the training volume may generate a greater proportion of likely responders to clinically significant improvements in FFI compared to MICT. However, it should be noted that there was no statistically significant difference in inter-individual FFI response between exercise interventions.

**Abbreviations**

MetS metabolic syndrome
CVD cardiovascular disease
FFI fitness-fatness index
EX-MET Exercise in the prevention of metabolic syndrome
MICT moderate-intensity continuous training
4HIIT high-volume high-intensity interval training
1HIIT high-volume high-intensity interval training
\( \dot{V}O_2 \) peak peak oxygen uptake
\( V_2 \) oxygen uptake
WHtR ratio of waist circumference-to-height
METs metabolic equivalents
T2D type 2 diabetes
DEXA dual-energy X-ray absorptiometry
HRpeak peak heart rate
RPE rate of perceived exertion
ANCOVA analysis of covariance
HRR heart rate reserve

**Declarations**

*Ethics approval and consent to participate*

This study was approved by the Medical Research Ethics Committee, The University of Queensland, Brisbane, Australia. Informed consent was obtained from all participants of this study.

*Consent for publication*

Not applicable

*Availability of data and material*
The datasets generated and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.

**Competing interest**

Joyce S. Ramos, Lance C. Dalleck, Mackenzie Fennell, Alex Martini, Talita Welmans, Rebecca Stennett, Shelley E. Keating, Robert G. Fassett, Jeff S. Coombes declare that they have no competing interests.

**Funding**

The Norwegian University Science and Technology and an unrestricted research grant from The Coca-Cola Company provided the funding to conduct this study. The funders of this study had no role in data collection, data analysis, data interpretation, or writing of this report.

**Author contributions**

JSR wrote the manuscript, collected, analysed and interpreted the data, and reviewed or edited and approved the final draft of the manuscript. JSR and JSC designed the study. JSC, LCD, MF, AM, TW, RS, SEK, and RGF also reviewed/edited and approved the final draft of the article. JSC is the guarantor of this study.

**Acknowledgements**

Investigators from the Norwegian University of Science and Technology designed the multicenter trial that this present study was derived from, as a sub-study. The corresponding author had full access to all the data of this study and had final responsibility for the decision to submit for publication. The Norwegian University Science and Technology and an unrestricted research grant from The Coca-Cola Company provided the funding to conduct this study. The funders of this study had no role in data collection, data analysis, data interpretation, or writing of this report.

**References**

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
2. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–72.
3. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care. 2005;28(2):391–7.
4. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation. 2005;112(4):505–12.
5. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108(13):1541–5.
6. Sloan RA, Haaland BA, Sawada SS, Lee IM, Sui X, Lee DC, et al. A Fit-Fat Index for Predicting Incident Diabetes in Apparently Healthy Men: A Prospective Cohort Study. PLoS One. 2016;11(6):e0157703.
7. Sloan RA, Sawada SS, Gando LIM, Kawakami Y, Okamoto R. T, et al. The Association of Fit-Fat Index with Incident Diabetes in Japanese Men: A Prospective Cohort Study. Sci Rep. 2018;8(1):569.
8. Edwards MK, Addoh O, Loprinzi PD. Predictive Validity of a Fitness Fatness Index in Predicting Cardiovascular Disease and All-Cause Mortality. Mayo Clin Proc. 2017;92(5):851.
9. Frith E, Loprinzi PD. The protective effects of a novel fitness-fatness index on all-cause mortality among adults with cardiovascular disease. Clin Cardiol. 2017;40(7):469–73.
10. Pattyn N, Cornelissen VA, Eshghi SR, Vanhees L. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials. Sports Med. 2013;43(2):121–33.

11. Weston KS, Wisloff U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br J Sports Med. 2014;48(16):1227–34.

12. Tjonna AE, Lee SJ, Rogno O, Stolen TO, Bye A, Haram PM, et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation. 2008;118(4):346–54.

13. Tjonna AE, Leinan IM, Bartnes AT, Jenssen BM, Gibala MJ, Winett RA, et al. Low- and high-volume of intensive endurance training significantly improves maximal oxygen uptake after 10-weeks of training in healthy men. PLoS One. 2013;8(5):e65382.

14. Trost SG, Owen N, Bauman AE, Sallis JF, Brown W. Correlates of adults' participation in physical activity: review and update. Med Sci Sports Exerc. 2002;34(12):1996–2001.

15. Ramos JS, Dalleck LC, Borrani F, Mallard AR, Clark B, Keating SE, et al. The effect of different volumes of high-intensity interval training on proinsulin in participants with the metabolic syndrome: a randomised trial. Diabetologia. 2016;59(11):2308–20.

16. Tjonna AE, Ramos JS, Pressler A, Halle M, Jungbluth K, Ermacora E, et al. EX-MET study: exercise in prevention on of metabolic syndrome - a randomized multicenter trial: rational and design. BMC Public Health. 2018;18(1):437.

17. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366(9491):1059–62.

18. Ramos JS, Ramos MV, Dalleck LC, Borrani F, Walker KB, Fassett RG, et al. Fitness is Independently Associated with Central Hemodynamics in Metabolic Syndrome. Med Sci Sports Exerc. 2016;48(8):1539–47.

19. Coombes J, Skinner T, Australia ESS. ESSA's student manual for health, exercise and sport assessment. Chatswood: Mosby; 2014.

20. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–81.

21. Wells JC, Fewtrell MS. Measuring body composition. Arch Dis Child. 2006;91(7):612–7.

22. Williams CJ, Gurd BJ, Bonafiglio JT, Voisin S, Li Z, Harvey N, et al. A Multi-Center Comparison of O2peak Trainability Between Interval Training and Moderate Intensity Continuous Training. Front Physiol. 2019;10:19.

23. Ramos JS, Dalleck LC, Borrani F, Beetham KS, Wallen MP, Mallard AR, et al. Low-volume high-intensity interval training is sufficient to ameliorate the severity of metabolic syndrome. Metab Syndr Relat Disord. 2017;15(7):319–28.

24. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of lipid research. 2005;46(11):2347–55.

25. Martinez J. Mitochondrial oxidative stress and inflammation: an slalom to obesity and insulin resistance. Journal of physiology biochemistry. 2006;62(4):303–6.

26. Duscha BD, Slentz CA, Johnson JL, Houmard JA, Bensimhon DR, Knetzger KJ, et al. Effects of exercise training amount and intensity on peak oxygen consumption in middle-age men and women at risk for cardiovascular disease. Chest. 2005;128(4):2788–93.

27. Ross R, de Lannoy L, Stotz PJ, editors. Separate effects of intensity and amount of exercise on interindividual cardiorespiratory fitness response. Mayo Clinic Proceedings; 2015: Elsevier.

28. Bouchard C, Rankinen T. Individual differences in response to regular physical activity. Medicine and science in sports and exercise. 2001;33(6).

29. Feitosa MF, Gaskill SE, Rice T, Rankinen T, Bouchard C, Rao D, et al. Major gene effects on exercise ventilatory threshold: the HERITAGE Family Study. J Appl Physiol. 2002;93(3):1000–6.

30. Mann TN, Lamberts RP, Lambert MI. High responders and low responders: factors associated with individual variation in response to standardized training. Sports Med. 2014;44(8):1113–24.

31. Wolperrn AE, Burgos DJ, Janot JM, Dalleck LC. Is a threshold-based model a superior method to the relative percent concept for establishing individual exercise intensity? a randomized controlled trial. BMC sports science medicine
32. Katch V, Weltman A, Sady S, Freedson P. Validity of the relative percent concept for equating training intensity. Eur J Appl Physiol Occup Physiol. 1978;39(4):219–27.

Tables

Table 1 Participants’ Characteristics

| Variable                  | MICT (n=26) | 4HIIT (n=25) | 1HIIT (n=26) |
|---------------------------|-------------|--------------|--------------|
| **Demographics**          |             |              |              |
| Age, years (mean ± SD)    | 55.0 ± 9.8  | 57.1 ± 9.2   | 57.1 ± 7.4   |
| Male, sex (%)             | 69          | 52           | 65           |
| Type 2 diabetes (%)       | 35          | 44           | 46           |
| Hypertensive (%)          | 73          | 76           | 77           |
| **Medications**           |             |              |              |
| ACEIs, %                  | 46          | 48           | 50           |
| Calcium antagonist, %     | 8           | 32           | 8            |
| Beta-blocker, %           | 12          | 4            | 15           |
| Statin, %                 | 40          | 56           | 54           |
| Acetylsalicylic, %        | 19          | 28           | 23           |
| Metformin, %              | 31          | 32           | 35           |

MICT, moderate-intensity continuous training; 4HIIT, 4x4 min high-intensity interval training; 1HIIT, 1x4 min high-intensity interval training; ACEIs, angiotensin-converting enzyme inhibitors; SD, standard deviation

Table 2 All participants – changes in Fitness-Fatness Index, metabolic syndrome risk factors, and body composition following the exercise interventions
| Outcome Variables                       | MICT (n=26) | 4HIIT (n=25) | 1HIIT (n=26) | Between group difference (p-value) |
|----------------------------------------|------------|--------------|--------------|-----------------------------------|
|                                        | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group |
| Fitness-Fatness Index                  |            |              |              |                     |            |              |              |                     |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| FFI (METs/WHtR)                        | 13.3 ± 4.7 | 14.2 ± 5.0   | 0.05         | 11.8 ± 2.9          | 13.7 ± 3.8 | <0.01       | 12.8 ± 3.5   | 14.2 ± 3.6 | <0.01           | 0.30       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| METs                                   | 7.9 ± 2.3  | 8.3 ± 2.3    | 0.12         | 7.0 ± 1.5           | 8.0 ± 1.9  | <0.01       | 7.6 ± 1.8    | 8.2 ± 1.9  | <0.01           | 0.26       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Relative VO_{2} peak (mL/kg/min)       | 27.6 ± 7.9 | 28.9 ± 8.0   | 0.11         | 24.6 ± 5.3          | 28.1 ± 6.8 | <0.01       | 26.5 ± 6.3   | 28.8 ± 6.7 | <0.01           | 0.25       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Absolute VO_{2} peak (L/min)           | 2.7 ± 0.8  | 2.8 ± 0.8    | 0.11         | 2.3 ± 0.6           | 2.6 ± 0.8  | <0.01       | 2.4 ± 0.7    | 2.6 ± 0.8  | <0.01           | 0.30       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| WHtR                                   | 0.61 ± 0.1 | 0.60 ± 0.1   | 0.01         | 0.60 ± 0.1          | 0.59 ± 0.1 | 0.09        | 0.60 ± 0.1   | 0.59 ± 0.1 | 0.03            | 0.82       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Metabolic Syndrome Risk Factors        |            |              |              |                     |            |              |              |                     |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Triglycerides (mmol/L)                 | 1.6 (0.7 to 6.6) | 1.6 (0.7 to 5.2) | 0.26    | 1.8 (0.6 to 6.5) | 1.8 (0.7 to 4.6) | 0.38 | 2.0 (0.7 to 2.8) | 1.6 (0.6 to 3.0) | 0.21 | 0.86 |
| HDL-C (mmol/L)                         | 1.1 ± 0.4  | 1.2 ± 0.4    | 0.30         | 1.0 (0.4)           | 1.2 ± 0.4  | 0.53        | 1.2 ± 0.4    | 1.3 ± 0.4  | 0.01            | 0.50       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| LDL-C (mmol/L)                         | 2.9 ± 0.8  | 2.7 ± 0.9    | 0.60         | 2.3 (0.2 to 6.5)    | 2.4 (1.3 to 6.7) | 0.12 | 2.4 (1.1 to 6.5) | 2.3 (1.0 to 4.7) | 0.23 | 0.22 |
| Total cholesterol (mmol/L)             | 4.8 ± 1.0  | 4.6 ± 1.0    | 0.13         | 4.1 (2.6 to 9.3)    | 4.6 (2.9 to 9.1) | 0.06 | 4.5 (3.1 to 9.3) | 4.2 (2.9 to 6.9) | 0.52 | 0.06 |
| Waist circumference (cm)               | 107 ± 12   | 105 ± 12     | 0.03         | 104 ± 10            | 102 ± 9    | 0.06        | 103 ± 12     | 101 ± 12  | <0.01           | 0.64       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Systolic BP (mm Hg)                    | 132 ± 12   | 126 ± 11     | <0.01        | 128 ± 14            | 129 ± 11   | 0.77        | 136 ± 16     | 128 ± 15  | <0.01           | 0.16       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Diastolic BP (mm Hg)                   | 87 ± 9     | 82 ± 8       | 0.01         | 83 ± 8              | 80 ± 7     | 0.05        | 82 ± 10     | 79 ± 10   | 0.08            | 0.88       |            |              |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Fasting glucose (mmol/L)               | 5.8 (4.6 to 16.4) | 5.7 (4.1 to 12.4) | 0.30    | 6.2 (3.6 to 13.6)   | 5.6 (4.4 to 12.7) | 0.74 | 6.2 (4.3 to 13.0) | 6.0 (4.4 to 14.3) | 0.09 | 0.50 |
| Body Composition                       |            |              |              |                     |            |              |              |                     |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |            |              |                  |
| Weight (kg)                            | 98.2 ± 16.8 | 97.4 ± 13.5 | 0.30         | 91.5 ± 13.5         | 90.0 ± 13.5 | 0.12 | 92.4 ± 20.1  | 91.0 ± 16.8 | 0.07 | 0.63 |
|                          | 17.7 | 19.4 |
|--------------------------|------|------|
| **Hip Circumference (cm)** | 114 ± 12 | 113 ± 11 |
|                          | 114 ± 13 | 113 ± 11 |
| **Total Body Fat (%)**    | 38.7 ± 9.0 | 40.2 ± 7.6 |
|                          | 38.2 ± 9.1 | 40.2 ± 7.6 |
| **Trunk Fat (%)**         | 42.1 ± 8.5 | 43.1 ± 7.0 |
|                          | 41.5 ± 8.4 | 43.1 ± 7.0 |
| **Android Fat (%)**       | 44.4 ± 8.0 | 45.1 ± 6.8 |
|                          | 44.0 ± 7.8 | 45.1 ± 6.8 |
| **Gynoid Fat (%)**        | 37.5 ± 9.7 | 39.2 ± 8.4 |
|                          | 37.3 ± 9.9 | 39.2 ± 8.4 |
| **Lean Body Mass (kg)**   | 56.9 ± 11.3 | 52.3 ± 9.8 |
|                          | 56.7 ± 11.4 | 52.3 ± 9.8 |
| **BMI (kg/m²)**           | 33 ± 6 | 32 ± 6 |
|                          | 32 ± 5 | 33 ± 5 |

MICT, moderate-intensity continuous training; 4HIIT, 4x4 min high-intensity interval training; 1HIIT, 1x4 min high-intensity interval training; FFI, Fitness-Fatness Index; MET, metabolic equivalent; VO₂peak, peak oxygen uptake; WHtR, waist circumference-to-height ratio; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; BP, blood pressure; BMI, body mass index; SD, standard deviation

*Table 3 Non-T2D participants - changes in Fitness-Fatness Index, metabolic syndrome risk factors, and body composition following the exercise interventions*
| Outcome Variables | MICT (n=17) | 4HIIT (n=14) | 1HIIT (n=14) | Baseline | Post | p-value within-group | Baseline | Post | p-value within-group | Baseline | Post | p-value within-group | Between group difference (p-value) |
|-------------------|------------|--------------|--------------|-----------|------|----------------------|-----------|------|----------------------|-----------|------|----------------------|----------------------------------|
| **Fitness-Fatness Index** | | | | | | | | | | | | | |
| FFI (METs/WHtR) | 14.1 ± 4.7 | 15.1 ± 5.3 | 0.11 | 11.7 ± 2.2 | 13.5 ± 2.9 | 0.05 | 12.3 ± 3.4 | 13.7 ± 3.5 | 0.01 | 0.83 |
| METs | 8.3 ± 2.2 | 8.7 ± 2.4 | 0.21 | 7.0 ± 1.2 | 7.9 ± 1.8 | 0.05 | 7.3 ± 1.8 | 8.0 ± 2.0 | 0.02 | 0.74 |
| Relative VO₂peak (mL/kg/min) | 29.0 ± 7.8 | 30.5 ± 8.3 | 0.21 | 24.4 ± 4.1 | 27.8 ± 6.2 | 0.05 | 25.7 ± 6.1 | 27.9 ± 6.9 | 0.02 | 0.72 |
| Absolute VO₂peak (L/min) | 2.8 ± 0.8 | 2.9 ± 0.8 | 0.20 | 2.3 ± 0.6 | 2.5 ± 0.9 | 0.07 | 2.4 ± 0.8 | 2.6 ± 0.9 | 0.06 | 0.61 |
| WHtR | 0.60 ± 0.07 | 0.59 ± 0.08 | 0.04 | 0.60 ± 0.05 | 0.59 ± 0.04 | 0.24 | 0.60 ± 0.1 | 0.59 ± 0.05 | 0.11 | 0.83 |
| **Metabolic Syndrome Risk Factors** | | | | | | | | | | | | | |
| Triglycerides (mmol/L) | 1.6 (0.7 to 4.0) | 1.5 (0.65 to 4.91) | 0.51 | 1.9 (1.1 to 6.5) | 1.7 (0.7 to 4.2) | 0.11 | 1.7 ± 0.7 | 1.6 ± 0.6 | 0.40 | 0.68 |
| HDL-C (mmol/L) | 1.2 ± 0.4 | 1.2 ± 0.3 | 0.44 | 1.2 ± 0.4 | 1.2 ± 0.4 | 0.67 | 1.4 ± 0.4 | 1.4 ± 0.4 | 0.46 | 0.63 |
| LDL (mmol/L) | 3.0 ± 0.8 | 2.9 ± 0.9 | 0.82 | 2.6 ± 1.1 | 2.9 ± 1.0 | 0.22 | 3.3 ± 1.4 | 3.0 ± 1.2 | 0.07 | 0.34 |
| Total cholesterol (mmol/L) | 5.0 ± 1.0 | 4.8 ± 1.0 | 0.55 | 4.7 ± 1.1 | 5.0 ± 1.2 | 0.34 | 4.9 (3.8 to 9.3) | 5.1 (3.6 to 6.9) | 0.06 | 0.36 |
| Waist circumference (cm) | 106 ± 13 | 104 ± 14 | 0.07 | 102 ± 11 | 100 ± 11 | 0.15 | 104 ± 14 | 100 ± 13 | 0.06 | 0.64 |
| Systolic BP (mm Hg) | 131 ± 14 | 125 ± 11 | 0.07 | 133 ± 16 | 130 ± 12 | 0.64 | 132 ± 15 | 123 ± 9 | 0.03 | 0.16 |
| Diastolic BP (mm Hg) | 87 ± 11 | 83 ± 8 | 0.06 | 85 ± 9 | 82 ± 8 | 0.20 | 82 ± 13 | 79 ± 11 | 0.22 | 0.82 |
| Fasting glucose (mmol/L) | 5.6 ± 0.7 | 5.5 ± 0.6 | 0.85 | 5.5 ± 0.9 | 5.4 ± 0.6 | 0.25 | 5.7 ± 0.8 | 5.5 ± 0.7 | 0.07 | 0.82 |
| **Body Composition** | | | | | | | | | | | | | |
| Weight (kg) | 97 ± 20 | 97 ± 21 | 0.45 | 91 ± 17 | 89 ± 13 | 0.21 | 94 ± 21 | 92.0 ± 20 | 0.14 | 0.43 |
|                          | 115 ± 13 | 115 ± 14 | 113 ± 8 | 112 ± 9 | 0.78 | 113 ± 10 | 112 ± 10 | 0.85 | 0.99 |
|--------------------------|----------|----------|---------|---------|------|----------|----------|------|------|
| **Hip Circumference**    |          |          |         |         |      |          |          |      |      |
| (cm)                     |          |          |         |         |      |          |          |      |      |
| **Total Body Fat (%)**   | 39.6 ± 9.5 | 39.5 ± 9.7 | 42.1 ± 6.3 | 41.7 ± 5.7 | 0.52 | 41.8 ± 6.1 | 41.1 ± 6.2 | 0.11 | 0.67 |
| **Trunk Fat (%)**        | 42.9 ± 8.9 | 42.7 ± 8.9 | 44.5 ± 5.6 | 44.2 ± 4.6 | 0.73 | 44.6 ± 5.2 | 43.9 ± 5.0 | 0.22 | 0.87 |
| **Android Fat (%)**      | 45.4 ± 8.5 | 45.5 ± 8.2 | 46.8 ± 4.2 | 46.7 ± 3.6 | 0.84 | 46.9 ± 4.0 | 46.2 ± 4.1 | 0.33 | 0.40 |
| **Gynoid Fat (%)**       | 39.0 ± 10.2 | 38.9 ± 10.6 | 41.5 ± 7.2 | 41.1 ± 7.2 | 0.46 | 41.1 ± 7.2 | 40.5 ± 7.4 | 0.22 | 0.56 |
| **Lean Body Mass (kg)**  | 55.4 ± 12.3 | 55.1 ± 12.7 | 50.2 ± 10.5 | 49.3 ± 9.6 | 0.12 | 52.2 ± 14.3 | 52.2 ± 14.6 | 0.83 | 0.26 |
| **BMI (kg/m²)**          | 32 ± 6   | 32 ± 6   | 31 ± 5   | 33 ± 5   | 0.04 | 33 ± 5   | 33 ± 4   | 0.19 | 0.82 |

MICT, moderate-intensity continuous training; 4HIIT, 4x4 min high-intensity interval training; 1HIIT, 1x4 min high-intensity interval training; FFI, Fitness-Fatness Index; MET, metabolic equivalent; V̇O₂peak, peak oxygen uptake; WHtR, waist circumference-to-height ratio; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; BP, blood pressure; BMI, body mass index; SD, standard deviation

Table 4 T2D participants - changes in Fitness-Fatness Index, metabolic syndrome risk factors, and body composition following the exercise interventions
| Outcome Variables | MICT (n=9) | 4HIIT (n=11) | 1HIIT (n=12) |
|-------------------|------------|--------------|--------------|
|                   | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Baseline   | Post         | p-value within-group | Between group difference (p-value) |
| **Fitness-Fatness Index** |            |              |                  |            |              |                  |            |              |                  |                                  |
| FFI (METs/WHtR)   | 11.7 ± 4.6 | 12.3 ± 4.1   | 0.19            | 11.9 ± 3.7 | 13.9 ± 4.9   | 0.02            | 13.4 ± 3.8 | 14.7 ± 3.9   | <0.01          | 0.21                      |
| METs              | 7.1 ± 2.2  | 7.4 ± 1.9    | 0.34            | 7.1 ± 1.9  | 8.1 ± 2.2    | 0.01            | 7.9 ± 1.9  | 8.5 ± 1.9    | <0.01          | 0.19                      |
| Relative VO₂peak (mL/kg/min) | 25.0 ± 7.8 | 26.0 ± 6.8   | 0.34            | 24.7 ± 6.8 | 28.4 ± 7.7   | 0.01            | 27.5 ± 6.5 | 29.8 ± 6.5   | <0.01          | 0.19                      |
| Absolute VO₂peak (L/min) | 2.4 ± 0.6  | 2.5 ± 0.5    | 0.37            | 2.4 ± 0.6  | 2.7 ± 0.7    | 0.01            | 2.4 ± 0.6  | 2.6 ± 0.6    | 0.01          | 0.37                      |
| WHtR              | 0.63 ± 0.1 | 0.62 ± 0.1   | 0.17            | 0.61 ± 0.1 | 0.60 ± 0.1   | 0.23            | 0.60 ± 0.1 | 0.59 ± 0.1   | 0.13          | 0.75                      |
| **Metabolic Syndrome Risk Factors** |            |              |                  |            |              |                  |            |              |                  |                                  |
| Triglycerides (mmol/L) | 1.6 (1.1 to 6.6) | 1.6 (1.0 to 5.2) | 0.21 | 1.7 (0.6 to 3.5) | 1.8 (1.0 to 4.6) | 0.42 | 1.8 ± 0.8 | 1.6 ± 0.6 | 0.39 | 0.24 |
| HDL-C (mmol/L)     | 1.0 ± 0.3  | 1.1 ± 0.6    | 0.52            | 1.0 (0.6 to 2.1) | 0.9 (0.9 to 2.2) | 0.66 | 1.0 ± 0.3 | 1.1 ± 0.2 | 0.01 | 0.64 |
| LDL (mmol/L)       | 2.7 ± 0.9  | 2.4 ± 0.7    | 0.16            | 1.7 (0.2 to 6.5) | 1.8 (1.3 to 6.7) | 0.26 | 2.1 ± 1.0 | 2.0 ± 0.7 | 0.94 | 0.65 |
| Total cholesterol (mmol/L) | 4.5 ± 1.0 | 4.2 ± 1.0 | 0.04 | 3.5 (2.6 to 9.3) | 3.8 (2.9 to 9.1) | 0.10 | 3.4 (3.1 to 7.2) | 3.8 (2.9 to 5.5) | 0.75 | 0.17 |
| Waist circumference (cm) | 109 ± 8 | 107 ± 8 | 0.28 | 105 ± 10 | 104 ± 10 | 0.21 | 103 ± 11 | 101 ± 11 | 0.02 | 0.90 |
| Systolic BP (mm Hg) | 134 ± 8 | 127 ± 10 | <0.01 | 123 ± 7 | 128 ± 9 | 0.17 | 141 ± 17 | 134 ± 18 | 0.01 | 0.03 |
| Diastolic BP (mm Hg) | 87 ± 6 | 82 ± 7 | 0.04 | 81 ± 6 | 78 ± 7 | 0.21 | 81 ± 6 | 79 ± 8 | 0.20 | 0.96 |
| Fasting glucose (mmol/L) | 6.7 (5.6 to 16.4) | 6.6 (4.3 to 12.4) | 0.21 | 6.6 (5.1 to 13.6) | 7.4 (5.2 to 12.7) | 0.48 | 7.7 (4.3 to 2.9) | 6.6 (6.0 to 14.3) | 0.24 | 0.41 |
| **Body Composition** |            |              |                  |            |              |                  |            |              |                  |                                  |
| Weight (kg)        | 100 ± 9 | 99 ± 11 | 0.51 | 94 (82 to 138) | 92 (83) | 0.38 | 91 ± 20 | 90 ± 20 | 0.31 | 0.99 |
|                         | 111 ± 10 | 112 ± 11 | 0.52 | 114 ± 15 | 113 ± 14 | 0.53 | 107 ± 12 | 108 ± 15 | 0.43 | 0.61 |
|-------------------------|----------|----------|-------|----------|----------|-------|----------|----------|-------|-------|
| **Hip Circumference**   |          |          |       |          |          |       |          |          |       |       |
| (cm)                    | 112 ± 11 | 114 ± 15 | 0.53 | 113 ± 14 | 107 ± 12 | 108 ± 15 | 0.43 | 0.61 |
| **Total Body Fat (%)**  | 36.9 ± 8.3 | 35.8 ± 7.7 | 0.14 | 39.3 ± 8.6 | 38.3 ± 9.5 | 0.06 | 35.7 ± 6.6 | 35.4 ± 6.9 | 0.71 | 0.48 |
| **Trunk Fat (%)**       | 40.7 ± 7.9 | 39.1 ± 7.1 | 0.16 | 42.7 ± 8.1 | 41.6 ± 9.2 | 0.07 | 40.0 ± 6.3 | 39.7 ± 6.3 | 0.59 | 0.54 |
| **Android Fat (%)**     | 42.5 ± 7.1 | 41.2 ± 6.6 | 0.14 | 44.4 ± 8.7 | 43.1 ± 9.4 | 0.11 | 42.3 ± 5.4 | 41.8 ± 5.7 | 0.35 | 0.51 |
| **Gynoid Fat (%)**      | 34.8 ± 8.3 | 34.4 ± 8.3 | 0.89 | 38.1 ± 8.6 | 36.7 ± 9.6 | 0.03 | 33.0 ± 6.4 | 32.5 ± 7.2 | 0.23 | 0.33 |
| **Lean Body Mass (%)**  | 59.8 ± 9.1 | 59.8 ± 8.2 | 0.90 | 55.5 ± 8.3 | 56.1 ± 9.0 | 0.25 | 54.9 ± 9.4 | 54.5 ± 9.8 | 0.26 | 0.31 |
| **BMI (kg/m²)**         | 34 (26 to 44) | 34 (24 to 36) | 0.20 | 30 (23 to 43) | 30.0 (28 to 42) | 0.44 | 31 ± 6 | 31 ± 5 | 0.14 | 0.91 |

MICT, moderate-intensity continuous training; 4HIIT, 4x4 min high-intensity interval training; 1HIIT, 1x4 min high-intensity interval training; FFI, Fitness-Fatness Index; MET, metabolic equivalent; \( \text{VO}_{2\text{peak}} \), peak oxygen uptake; WHtR, waist circumference-to-height ratio; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; BP, blood pressure; BMI, body mass index; SD, standard deviation

**Figures**
Figure 1

Consort Flow Diagram for FFI sub-study. 1HIIT, 1 x 4 min high-intensity interval training; 4HIIT, 4 x 4 min high-intensity interval training; MICT, moderate-intensity continuous training.
Figure 2

Proportions of response categories in FFI change following exercise interventions in participants diagnosed with MetS with or without T2D